Journal
ACS SYNTHETIC BIOLOGY
Volume 9, Issue 6, Pages 1263-1269Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acssynbio.0c00097
Keywords
CRISPR/Cas9; genomic safe harbor; HEK cells; recombinase-mediated cassette exchange; site-specific integration; therapeutic protein
Categories
Funding
- National Research Foundation of Korea (NRF) - Korea government (MSIT) [2020R1A2C1003235, 2018R1C1B6001423]
- Novo Nordisk Foundation [NNF10CC1016517]
- National Research Foundation of Korea [2020R1A2C1003235, 2018R1C1B6001423] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
Human cell lines are being increasingly used as host cells to produce therapeutic glycoproteins, due to their human glycosylation machinery. In an attempt to develop a platform for generating isogenic human cell lines producing therapeutic proteins based on targeted integration, three well-known human genomic safe harbors (GSHs)-AAVS1, CCRS, and human ROSA26 loci-were evaluated with respect to the transgene expression level and stability in human embryonic kidney (HEK293) cells. Among the three GSHs, the AAVS1 locus showed the highest eGFP expression with the highest homogeneity. Transgene expression at the AAVS1 locus was sustained without selection for approximately 3 months. Furthermore, the CMV promoter showed the highest expression, followed by the EF1 alpha, SV40, and TK promoters at the AAVS1 locus. Master cell lines were created using CRISPR/Cas9-mediated integration of the landing pad into the AAVS1 locus and were used for faster generation of recombinant cell lines that produce therapeutic proteins with recombinase-mediated cassette exchange.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available